StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) shareholders

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)

Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
76.2%
82M of 108M shares
Institutional holders
422
129 new, 54 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
2 buys · 108 sales
Net sold $94.73M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.9,614,2178.90%13G (passive) amendmentSep 30, 2026
Ingalls & Snyder LLC7,263,4666.80%13G (passive) amendmentDec 31, 2025
Joseph K. Belanoff6,822,3356.30%13G (passive) amendmentDec 31, 2024
Renaissance Technologies Holdings Corporation
Joint filing with Renaissance Technologies LLC (5.47%)
5,758,5285.47%13G (passive) amendmentDec 31, 2025
G. Leonard Baker, Jr.5,512,6965.30%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CORTValueChange% of portfolio
BlackRock, Inc.12,432,02311.50%$1.08B+280,7470.02%
Ingalls & Snyder LLC7,934,5077.34%$689.91M+325,79118.83%
Renaissance Technologies LLC5,261,6284.87%$457.50M−421,1550.63%
Vanguard Portfolio Management LLC5,044,6384.67%$438.63M+224,0700.02%
Vanguard Capital Management LLC4,172,4823.86%$362.80M+95,2860.01%
Parallel Advisors, LLC3,962,1773.67%$344.51M−15,2275.25%
FMR LLC3,337,6183.09%$290.21M+147,4260.01%
State Street Corp3,279,3813.03%$285.15M+78,4350.01%
Aqr Capital Management LLC2,582,5612.39%$224.55M+2,176,3560.08%
Geode Capital Management, LLC2,532,1982.34%$220.21M−181,3210.01%
First Trust Advisors LP1,829,5451.69%$159.08M−343,8310.09%
Tang Capital Management LLC1,500,0001.39%$130.43M–5.92%
UBS Group AG1,377,6581.27%$119.79M+13,9900.02%
Dimensional Fund Advisors LP1,318,8211.22%$114.68M−234,3140.02%
Charles Schwab Investment Management Inc1,157,5801.07%$100.65M+37,6210.01%
Morgan Stanley1,137,5591.05%$98.91M+118,7140.01%
D. E. Shaw & Co., Inc.883,0010.82%$76.78M−298,3470.04%
Cerity Partners LLC797,1190.74%$69.31M+65,4300.08%
Mpm Bioimpact LLC771,0280.71%$67.04M−214,6724.09%
Northern Trust Corp753,7960.70%$65.54M+110,6380.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202642282M76.2%129 / 146109 / 5411M7M
Q1 202635280M73.6%69 / 114128 / 10124M12M
Q4 202539077M70.9%62 / 120157 / 947M9M
Q3 202542978M72.2%62 / 145157 / 507M8M
Q2 202542279M73.2%71 / 155157 / 658M12M
Q1 202542283M77.2%104 / 126146 / 416M7M
Q4 202436784M78.1%81 / 116124 / 304M8M
Q3 202432189M82.1%64 / 106106 / 2721M5M
Q2 202428690M82.8%37 / 104114 / 333M11M
Q1 202428597M89.8%54 / 11089 / 4016M5M
Q4 202327386M79.8%56 / 8293 / 268M4M
Q3 202324683M76.3%40 / 8292 / 166M4M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

304 funds held CORT in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CORTValue% of fundAs of
iShares Core S&P Small-Cap ETF5,753,8345.32%$500.30M0.45%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,893,8422.68%$251.62M0.01%Jun 30, 2026
Vanguard Small-Cap Index Fund2,093,4411.94%$182.02M0.10%Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund1,810,9371.68%$157.46M5.60%Jun 30, 2026
Fidelity Contrafund1,317,5291.22%$114.56M0.06%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,205,9001.12%$104.85M0.22%Jun 30, 2026
Vanguard Extended Market Index Fund1,095,9431.01%$95.29M0.10%Jun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF876,5330.81%$76.21M0.45%Jun 30, 2026
iShares S&P Small-Cap 600 Growth ETF858,5830.79%$74.65M0.91%Jun 30, 2026
Vanguard Tax-Managed Small-Cap Fund615,7850.57%$53.54M0.47%Jun 30, 2026
iShares Russell Mid-Cap Growth ETF560,1170.52%$48.70M0.23%Jun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF542,6200.50%$47.18M0.91%Jun 30, 2026
Select Biotechnology Portfolio506,7460.47%$35.21M0.67%May 31, 2026
Fidelity Extended Market Index Fund480,5720.44%$33.39M0.08%May 31, 2026
Fullerthaler Behavioral Small-Cap Growth470,0000.43%$40.87M0.66%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Joseph K. BelanoffChief Executive Officer, Director3,415,4893.16%Jun 2, 2026
Roberto Wandenkolk VieiraPresident, Oncology3,9460.00%Nov 4, 2026
Justin Frederick GunnSee Remarks12,1910.01%Oct 5, 2026
Joseph Douglas LyonSee Remarks5,6830.01%Oct 5, 2026
Gary Charles RobbChief Business Officer94,9140.09%Sep 28, 2026
Atabak MokariChief Financial Officer16,3040.02%Sep 3, 2026
William GuyerChief Development Officer10,3870.01%Sep 3, 2026
Hazel HuntChief Scientific Officer255,4370.24%Mar 3, 2026
Daniel N. Swisher JRDirector0–Nov 13, 2026
James N. WilsonDirector1,543,9071.43%Oct 16, 2026
Kimberly ParkDirector0–Aug 28, 2026
David L. MahoneyDirector1,282,8391.19%Aug 20, 2026
G. Leonard Baker JrDirector5,525,9785.11%May 26, 2026
Gregg H. AltonDirector––May 26, 2026
Joshua M. MurrayDirector––May 26, 2026
Gillian CannonDirector0–Sep 11, 2025
Sean Maduck–18,9380.02%Nov 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Daniel N. Swisher JR
Director
Nov 10, 2026Sale(10b5-1 plan)−1,500$74.07$111.10K0
Daniel N. Swisher JR
Director
Nov 10, 2026Option exercise+400$10.50$4.20K1,500
Daniel N. Swisher JR
Director
Nov 10, 2026Option exercise+1,100$14.08$15.49K1,100
Sean Maduck
–
Nov 3, 2026Sale(10b5-1 plan)−4,542$82.68$375.51K9,938
Sean Maduck
–
Nov 3, 2026Sale(10b5-1 plan)−8,617$82.02$706.76K14,480
Sean Maduck
–
Nov 3, 2026Option exercise+13,159$8.27$108.82K23,097
Sean Maduck
–
Nov 2, 2026Sale(10b5-1 plan)−11,841$81.42$964.07K9,938
Sean Maduck
–
Nov 2, 2026Option exercise+11,841$8.27$97.93K21,779
Roberto Wandenkolk Vieira
President, Oncology
Nov 2, 2026Sale(10b5-1 plan)−1,676$81.52$136.63K3,946
Roberto Wandenkolk Vieira
President, Oncology
Nov 2, 2026Sale(10b5-1 plan)−6,657$80.73$537.44K5,622
Roberto Wandenkolk Vieira
President, Oncology
Nov 2, 2026Option exercise+8,333$21.63$180.24K12,279
James N. Wilson
Director
Oct 15, 2026Sale(10b5-1 plan)−300$116.30$34.89K1,054,543
James N. Wilson
Director
Oct 15, 2026Sale(10b5-1 plan)−3,046$115.39$351.48K1,054,843
James N. Wilson
Director
Oct 15, 2026Sale(10b5-1 plan)−6,654$114.48$761.72K1,057,889
Roberto Wandenkolk Vieira
President, Oncology
Oct 2, 2026Sale(10b5-1 plan)−5,147$116.58$600.06K3,946
Roberto Wandenkolk Vieira
President, Oncology
Oct 2, 2026Sale(10b5-1 plan)−2,086$115.73$241.41K9,093
Roberto Wandenkolk Vieira
President, Oncology
Oct 2, 2026Sale(10b5-1 plan)−1,100$114.52$125.97K11,179
Roberto Wandenkolk Vieira
President, Oncology
Oct 2, 2026Option exercise+8,333$21.63$180.24K12,279
Joseph Douglas Lyon
See Remarks
Oct 2, 2026Sale(10b5-1 plan)−4,744$116.54$552.87K5,683
Joseph Douglas Lyon
See Remarks
Oct 2, 2026Sale(10b5-1 plan)−4,446$115.70$514.39K10,427
Joseph Douglas Lyon
See Remarks
Oct 2, 2026Option exercise+5,833$19.26$112.34K14,873
Joseph Douglas Lyon
See Remarks
Oct 2, 2026Option exercise+3,357$13.56$45.52K9,040
Sean Maduck
See Remarks
Oct 2, 2026Sale(10b5-1 plan)−8,744$116.55$1.02M9,938
Sean Maduck
See Remarks
Oct 2, 2026Sale(10b5-1 plan)−15,843$116.12$1.84M18,682
Sean Maduck
See Remarks
Oct 2, 2026Option exercise+24,587$8.27$203.33K34,525
Joseph Douglas Lyon
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−810$115.40$93.47K5,683
Joseph Douglas Lyon
See Remarks
Oct 1, 2026Option exercise+810$13.56$10.98K6,493
Sean Maduck
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−413$115.54$47.72K9,938
Sean Maduck
See Remarks
Oct 1, 2026Option exercise+413$8.27$3.42K10,351
Gary Charles Robb
Chief Business Officer
Sep 24, 2026Gift−17,100––14,056
Gary Charles Robb
Chief Business Officer
Sep 24, 2026Gift+5,000––20,571
Gary Charles Robb
Chief Business Officer
Sep 24, 2026Gift+5,000––20,571
Gary Charles Robb
Chief Business Officer
Sep 17, 2026Option exercise+17,493$8.27$144.67K31,156
Roberto Wandenkolk Vieira
President, Oncology
Sep 16, 2026Sale(10b5-1 plan)−296$100.82$29.84K3,946
James N. Wilson
Director
Sep 15, 2026Sale(10b5-1 plan)−6,800$110.27$749.84K1,067,743
James N. Wilson
Director
Sep 15, 2026Sale(10b5-1 plan)−400$110.84$44.34K1,067,343
James N. Wilson
Director
Sep 15, 2026Sale(10b5-1 plan)−2,800$111.70$312.76K1,064,543
Joseph Douglas Lyon
See Remarks
Sep 14, 2026Sale(10b5-1 plan)−2,188$114.12$249.69K5,683
Joseph Douglas Lyon
See Remarks
Sep 14, 2026Option exercise+7,404$13.56$100.40K15,683
Joseph Douglas Lyon
See Remarks
Sep 14, 2026Sale(10b5-1 plan)−7,812$113.32$885.26K7,871
Joseph Douglas Lyon
See Remarks
Sep 14, 2026Option exercise+2,596$11.35$29.46K8,279
Gary Charles Robb
Chief Business Officer
Sep 2, 2026Tax withholding−91$113.38$10.32K13,663
Joseph Douglas Lyon
See Remarks
Sep 2, 2026Tax withholding−72$113.38$8.16K5,683
Sean Maduck
See Remarks
Sep 2, 2026Tax withholding−117$113.38$13.27K9,938
Atabak Mokari
Chief Financial Officer
Sep 2, 2026Tax withholding−102$113.38$11.56K16,304
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−974$112.40$109.48K12,694
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Tax withholding−102$113.38$11.56K4,242
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Option exercise+58,333$21.63$1.26M62,575
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−23,600$109.35$2.58M38,975
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−23,770$110.70$2.63M15,205
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−1,537$111.37$171.18K13,668
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−1,606$113.72$182.63K11,088
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−5,621$114.58$644.05K5,467
Roberto Wandenkolk Vieira
President, Oncology
Sep 2, 2026Sale(10b5-1 plan)−1,225$115.44$141.41K4,242
Gary Charles Robb
Chief Business Officer
Sep 1, 2026Award+164––13,754
Gary Charles Robb
Chief Business Officer
Sep 1, 2026Award+164$113.38$18.59K13,590
Joseph Douglas Lyon
See Remarks
Sep 1, 2026Award+130$113.38$14.74K5,625
Joseph Douglas Lyon
See Remarks
Sep 1, 2026Award+130––5,755
Sean Maduck
See Remarks
Sep 1, 2026Award+150––10,055
Sean Maduck
See Remarks
Sep 1, 2026Option exercise+25,000$8.27$206.75K34,755

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.86%
9M shares short
Days to cover
8.1
At 1M shares a day
Change since last report
+6.3%
From 9M shares
Short volume, 20 days
50.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Corcept Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,077 shares on Sep 3, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Daniel N. Swisher JR
Director
Nov 10, 20261,500$112.54KNov 10, 2026Exercise of Stock Options
Joseph Douglas Lyon
Officer
Oct 1, 202610,000$1.15MOct 1, 2026stock option exercise
James N. Wilson
Director
Sep 15, 202630,000$3.34MSep 15, 2026STOCK OPTION AWARDS
Joseph Douglas Lyon
Officer
Sep 14, 202610,000$1.13MSep 14, 2026Stock Option Exercise
Roberto Wandenkolk Vieira
Officer
Sep 2, 202675,295$8.34MSep 2, 2026Stock Option Exercise
Kimberly Park
Director
Aug 26, 202626,685$3.27MAug 26, 2026Stock Option Exercise
Sean Maduck
Officer
Aug 25, 2026175,000$21.98MAug 25, 2026Stock Option Award
David L. Mahoney
Director
Aug 18, 2026103,606$12.16MAug 18, 2026OPEN MARKET PURCHASES AQCUIRED BETWEEN: 5/22/20 - 4/12/24
Gary Charles Robb
Officer
Aug 17, 202610,000$1.16MAug 17, 2026Owned Shares
William Guyer
Officer
Aug 4, 202620,000$2.26MAug 4, 2026Stock Option Exercise
Joseph Douglas Lyon
Officer
Aug 3, 20261,540$175.81KAug 3, 2026Option Exercise
Atabak Mokari
Officer
Jul 30, 202640,000$4.59MJul 30, 2026Stock Option Exercises
William Guyer
Officer
Jul 7, 202620,000$1.86MJul 7, 2026Stock Option Exercise
David L. Mahoney
Director
Jun 16, 202620,000$1.67MJun 16, 2026Employee Compensation
James N. Wilson
Director
Jun 16, 202630,000$2.50MJun 16, 2026STOCK OPTION AWARDS

See a number that looks wrong?